Target Pairs
Intelligence → Decision → Tool → ServiceCheckpoint × Angiogenesis
PD-1 × VEGF-A
Combines PD-1 checkpoint blockade with VEGF-A anti-angiogenesis in one molecule; flagship pair with ivonescimab/AK112 (A…
Golden Pair
Checkpoint × AngiogenesisPD-L1 × VEGF-A
Axis clinically validated (atezolizumab+bevacizumab FDA-approved 1L HCC 2020) but no PD-L1×VEGF bispecific approved yet;…
Golden Pair
Tumor Target × T-cell EngagerDLL3 × CD3
The reference T-cell engager pair: DLL3 is a tumor-selective Notch ligand enriched in SCLC/neuroendocrine tumors; tarlat…
Golden Pair
Dual Tumor TargetEGFR × LGR5
Emerging pair combining EGFR (mature, validated) with LGR5 (Wnt/stemness, tumor-initiating cell marker) to target resist…
Golden Pair
Dual Receptor TargetingEGFR × MET
Mature dual-receptor pair with an approved reference asset: amivantamab (EGFR×MET, 4 FDA NSCLC indication bullets; SC FA…
Golden Pair
First-phase Golden Pairs. Watch pairs and scores update as evidence is reviewed.